Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: fluorouracil
Drug: gemcitabine hydrochloride
Drug: leucovorin calcium
Drug: oxaliplatin
Procedure: adjuvant therapy
Procedure: conventional surgery
Procedure: neoadjuvant therapy
Radiation: radiation therapy

First Posted Date: 2004-08-05

Last Posted Date: 2023-09-29

Lead Sponsor: University of Nebraska

Target Recruit Count: 29

Registration Number: NCT00089024

Locations: 🇺🇸
Eppley Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska, United States

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced or Metastatic Cancer of the Esophagus

Phase 1

Completed

Conditions: Esophageal Cancer

First Posted Date: 2004-07-30

Last Posted Date: 2012-05-24

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 26

Registration Number: NCT00002984

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States

High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: CMF regimen
Biological: filgrastim
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: mesna
Drug: epirubicin hydrochloride
Drug: fluorouracil
Procedure: peripheral blood stem cell transplantation
Drug: methotrexate
Drug: tamoxifen citrate
Radiation: low-LET electron therapy
Radiation: low-LET photon therapy

First Posted Date: 2004-07-29

Last Posted Date: 2013-04-04

Lead Sponsor: ETOP IBCSG Partners Foundation

Target Recruit Count: 344

Registration Number: NCT00002784

Locations: 🇦🇺
Queen Elizabeth Hospital, Adelaide, South Australia, Australia
🇦🇺
Royal Prince Alfred Hospital, Sydney, Sydney, New South Wales, Australia
🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia

and more 8 locations

Tamoxifen in Treating Women With High-Risk Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

First Posted Date: 2004-07-29

Last Posted Date: 2020-04-01

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 672

Registration Number: NCT00002542

Locations: 🇨🇦
Credit Valley Hospital, Mississauga, Canada
🇨🇦
Cancer Centre of Southeastern Ontario at Kingston, Kingston, Canada
🇨🇦
Stronach Regional Health Centre at Southlake, Newmarket, Canada

and more 45 locations

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth Cancer

Phase 1

Completed

Conditions: Head and Neck Cancer

First Posted Date: 2004-07-26

Last Posted Date: 2013-06-26

Lead Sponsor: Robert H. Lurie Cancer Center

Registration Number: NCT00004901

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

Combination Chemotherapy and Interferon Alfa Followed by Surgery and/or Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer

Phase 2

Terminated

Conditions: Esophageal Cancer

First Posted Date: 2004-07-26

Last Posted Date: 2012-06-12

Lead Sponsor: Northwestern University

Registration Number: NCT00004897

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States

Biological Therapy Plus Chemotherapy in Treating Patients With Metastatic or Recurrent Kidney Cancer

Phase 1

Completed

Conditions: Kidney Cancer

First Posted Date: 2004-07-22

Last Posted Date: 2013-12-10

Lead Sponsor: University of New Mexico

Target Recruit Count: 35

Registration Number: NCT00003585

Locations: 🇺🇸
University of New Mexico Cancer Research & Treatment Center, Albuquerque, New Mexico, United States

Combination Chemotherapy in Treating Patients With Stage IIB, Stage III, or Stage IV Cancer of the Nasopharynx

Phase 2

Conditions: Head and Neck Cancer

First Posted Date: 2004-07-19

Last Posted Date: 2009-02-09

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT00004164

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States